SCHEMBL12796397

SCHEMBL12796397

O=C(c1cnc(N[C@@H]2C[C@H]3CC[C@@H]2O3)nc1C(F)(F)F)N1CCC(F)(F)C1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ VNN1 O95497 3/20 0.37
▸ SCD O00767 1/20 0.36
▸ CNR2 P34972 8/20 0.36
▸ SYK P43405 3/20 0.35
▸ CXCR4 P61073 1/20 0.35
▸ CYP1A2 P05177 3/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ PLAT P00750 1/20 0.35
▸ CYP2C9 P11712 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ DPP8 Q6V1X1 1/20 0.34
▸ DPP7 Q9UHL4 1/20 0.34
▸ PDE5A O76074 1/20 0.34
▸ PDE9A O76083 1/20 0.34
▸ SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12796398 0.95 SCD (0.39) VNN1SCDCNR2SYKCXCR4
SCHEMBL541416 0.89 CXCR4 (0.37) VNN1SCDCNR2CXCR4CYP1A2
SCHEMBL12796394 0.89 CXCR4 (0.37) VNN1SCDCNR2CXCR4CYP1A2
SCHEMBL12796373 0.85 LRRK2 (0.41) SCDCNR2SYKCXCR4CYP1A2
SCHEMBL12796381 0.85 LRRK2 (0.41) SCDCNR2SYKCXCR4CYP1A2
SCHEMBL12796366 0.84 CXCR4 (0.37) SCDCNR2SYKCXCR4CYP1A2
SCHEMBL12796374 0.84 CXCR4 (0.37) SCDCNR2SYKCXCR4CYP1A2
SCHEMBL12796026 0.81 PDE5A (0.44) CNR2CYP1A2CYP2D6CYP2C19CYP2C9
SCHEMBL12796021 0.81 PDE5A (0.44) CNR2CYP1A2CYP2D6CYP2C19CYP2C9
SCHEMBL12795985 0.78 MAPT (0.47) CNR2CYP1A2CYP2D6CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 VNN1 3256/4885SCD 1093/4885CNR2 1/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 VNN1 2974/4885SCD 1251/4885CNR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback